Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuro Oncol. 2011 Jan;13(1):3-13. doi: 10.1093/neuonc/noq169. Epub 2010 Dec 10.

Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Author information

1
Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Unit 442, FC7.3021, Houston, TX 77030-4009, USA. aheimber@mdanderson.org

Abstract

With the recent approval by the FDA of an immunotherapy for prostate cancer and another positive immunotherapy trial in melanoma, immunotherapy may finally be coming of age. So what will it take for it to become part of the standard treatment for glioblastoma? To put this question into perspective, we summarize critical background information in neuro-immunology, address immunotherapy clinical trial design, and discuss a number of extrinsic factors that will impact the development of immunotherapy in neuro-oncology.

PMID:
21149252
PMCID:
PMC3018912
DOI:
10.1093/neuonc/noq169
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems Icon for PubMed Central
    Loading ...
    Support Center